|This article does not cite any sources. (September 2016) (Learn how and when to remove this template message)|
|Trade names||Uroxatral, others|
|By mouth (tablets)|
|Biological half-life||10 hours|
|Excretion||Feces (69%) and Urine (24%)|
|Chemical and physical data|
|Molar mass||389.449 g/mol|
|3D model (Jmol)|
Alfuzosin (INN, provided as the hydrochloride salt) is a pharmaceutical drug of the α1 blocker class. As an antagonist of the α1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH).
Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradenames Xat, Xatral, Prostetrol and Alfural. Alfuzosin was approved by the U.S. FDA for treatment of BPH in June 2003.
Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.
- Uroxatral (alfuzosin HCl) Extended-Release Tablets Prescribing Information
- Alfuzosin (General information from the NIH)
|This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|